Combination strategies using benzimidazoles (mebendazole, albendazole, flubendazole, and fenbendazole) focus on achieving synergistic cell killing, overcoming multidrug resistance, and lowering individual drug toxicities. By pairing these microtubule-disrupting and signal-modulating agents with standard cytotoxic chemotherapies, targeted inhibitors, radiation, or immunotherapies, researchers have uncovered several promising combination protocols across diverse tumor types.
1. Combination with Conventional Chemotherapy
Temozolomide (TMZ) & Lomustine (CCNU) in Brain Tumors: In a Phase 1 clinical trial for recurrent high-grade glioma, oral mebendazole (MBZ) was combined with standard temozolomide and re-radiation, as well as single-agent CCNU. The study established a maximum recommended Phase 2 dose of 1600 mg TDS (4800 mg/day) for MBZ when paired with temozolomide or temozolomide-radiation, and 800 mg TDS (2400 mg/day) when combined with CCNU. The combinations demonstrated long-term clinical safety with acceptable, reversible hepatic toxicity.
Bortezomib in Multiple Myeloma: Albendazole (ABZ) resensitizes chemoresistant multiple myeloma cells to the proteasome inhibitor bortezomib. ABZ inhibits the NF-κB signaling pathway and depletes aldehyde dehydrogenase-positive (ALDH+) myeloma stem-like cells, resulting in synergistic G2/M phase cell-cycle arrest and apoptosis.
Taxanes & Vinca Alkaloids: MBZ acts synergistically with docetaxel in prostate cancer models. In hematological cancers, flubendazole (FLBZ) binds tubulin at a site distinct from Vinca alkaloids; FLBZ retains potency in P-glycoprotein-overexpressing cells resistant to vinblastine and exhibits synergistic cytotoxicity when combined with vincristine or vinblastine in acute myeloid leukemia and myeloma xenografts.
Cisplatin, 5-Fluorouracil (5-FU) & Methotrexate: MBZ potentiates cisplatin in head and neck squamous cell carcinoma (HNSCC) by suppressing proliferation and enhancing cellular differentiation. MBZ also shows synergistic cytotoxicity with 5-FU in gastric cancer models and with methotrexate in triple-negative breast cancer (TNBC) cells.
2. Combination with Targeted Therapeutics & Deubiquitinase Inhibitors
MEK & MAPK Inhibitors: Combining MBZ with the MEK inhibitor trametinib suppresses refractory NRASQ61K-mutant melanoma by enhancing the dual inhibition of MEK/ERK phosphorylation, downregulating c-MYC and Bcl-2, and promoting cleavage of caspase-3 and PARP. Similarly, MBZ augments the efficacy of sorafenib in hepatocellular carcinoma by enhancing MAPK pathway blockade and suppressing VEGF and Bcl-2 expression.
Hedgehog (Hh) Signaling Blockers: MBZ inhibits primary cilium formation and suppresses Smoothened (SMO) signaling, demonstrating additive Hh pathway inhibition when combined with vismodegib in medulloblastoma. MBZ remains active even in tumor clones that develop vismodegib resistance due to SMO gene mutations.
Tyrosine Kinase Inhibitors (TKIs) in CML: In chronic myeloid leukemia (CML), MBZ overcomes TKI resistance and acts synergistically with imatinib and dasatinib to induce apoptosis and G2/M arrest.
USP5 Deubiquitinase Inhibitors: MBZ synergizes with the USP5 inhibitor WP1130 in multiple myeloma, promoting the proteasomal degradation of the oncogenic transcription factor c-Maf and delaying tumor growth in mouse xenografts.
3. Combination with Ionizing Radiation (Radiosensitization)
Albendazole as a Brain Metastasis Radiosensitizer: Pretreatment with ABZ (at nanomolar concentrations) arrests metastatic melanoma and small cell lung cancer (SCLC) cells in the G2/M phase—the most radiosensitive phase of the cell cycle. Combining short-course ABZ (12 hours) with 2 Gy irradiation yields supra-additive and synergistic cell killing (CI<0.90), accompanied by increased H2AX phosphorylation, PARP cleavage, and caspase-9 activation.
Mebendazole Radiosensitization: MBZ significantly potentiates radiation therapy in triple-negative breast cancer (TNBC) models by modulating DNA damage response proteins (increasing γH2AX markers), as well as in intracranial malignant meningioma models.
4. Combination with Immunotherapy & Oncolytic Viruses
Oncolytic Virus M1 (OVM1): Combining ABZ with Oncolytic Virus M1 produces strong synergistic antitumor efficacy in prostate cancer and glioma immunocompetent models. Rather than altering viral replication, ABZ enhances CD8+ T-cell infiltration and activation (upregulating Ki67, CD44, CD69, IFN-γ, granzyme B, and TNF-α) while downregulating PD-1. Adding anti-CTLA4 antibodies to this combination further enhances systemic tumor regression.
Repolarization of Tumor-Associated Macrophages: MBZ promotes the phenotypic switch of tumor-associated macrophages from pro-tumor M2 to anti-tumor M1 phenotypes, enhancing natural killer (NK) cell toxicity and T-cell-mediated surveillance within the tumor microenvironment.
5. Repurposed Non-Chemotherapy Cocktails & Nanotechnology
MBZ + Sulindac (NSAID Chemoprevention): In the ApcMin/+ mouse model of Familial Adenomatous Polyposis (FAP) and colorectal cancer, combining oral MBZ (35 mg/kg) with the NSAID sulindac achieved a 90% reduction in intestinal adenomas and polyps. This cocktail synergistically downregulates COX-2, VEGFR2 phosphorylation, MYC, and Bcl-2.
MBZ + Cimetidine / Metformin: The H2-receptor antagonist cimetidine inhibits hepatic cytochrome P450 enzymes, reducing first-pass metabolism and elevating systemic MBZ plasma levels. Combining MBZ with metformin or itraconazole targets metabolic and Hedgehog pathways simultaneously.
Nanocarrier Formulations: To overcome poor aqueous solubility, ABZ has been integrated into zinc oxide nanoparticles (ZnO NPs), zein nanoparticles, and cyclodextrin metal-organic frameworks (MOFs), demonstrating synergistic cytotoxicity with low-dose doxorubicin or standard chemotherapeutics via ROS-associated immunogenic cell death.
References
Aliabadi, A., Moradi, S. Z., Abdian, S., Fakhri, S., & Echeverría, J. (2025). Critical dysregulated signaling pathways in drug resistance: Highlighting the repositioning of mebendazole for cancer therapy. Frontiers in Pharmacology, 16, Article 1631419. https://doi.org/10.3389/fphar.2025.1631419
Alavi, S. E., & Ebrahimi Shahmabadi, H. (2021). Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharmaceutical Journal, 29(5), 434–445. https://doi.org/10.1016/j.jsps.2021.04.004
Al-Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Khan, A., Shkoor, M., Bani-Yaseen, A. D., Al Zoubi, M. S., & Agouni, A. (2026). Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment. European Journal of Medicinal Chemistry, 316, Article 118987. https://doi.org/10.1016/j.ejmech.2026.118987
Badawy, M. A. S., Bräse, S., Ali, T. F. S., Abdel-Aziz, M., & Abdel-Rahman, H. M. (2025). Biologically active benzimidazole hybrids as cancer therapeutics: Recent advances. Pharmaceuticals, 18(10), Article 1454. https://doi.org/10.3390/ph18101454
Bai, W., Tang, X., Xiao, T., Qiao, Y., Tian, X., Zhu, B., Chen, J., Chen, C., Li, Y., Lin, X., Cai, J., Lin, Y., Zhu, W., Yan, G., Liang, J., & Hu, J. (2024). Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation. Molecular Therapy Oncology, 32, Article 200813. https://doi.org/10.1016/j.omton.2024.200813
Becerril-Vega, J., Hernández-Campos, A., González-Hernández, I., Flores-Ramos, M., Castillo, R., Leyva-Gómez, G., Mayet-Cruz, L., & Jung-Cook, H. (2023). Development and pharmacokinetic evaluation of two parenteral formulations of albendazole using prodrug and cosolvent approaches. AAPS PharmSciTech, 24(6), Article 158. https://doi.org/10.1208/s12249-023-02613-9
Castro, L. S. E. P. W., Kviecinski, M. R., Ourique, F., Parisotto, E. B., Grinevicius, V. M. A. S., Correia, J. F. G., Wilhelm Filho, D., & Pedrosa, R. C. (2016). Albendazole as a promising molecule for tumor control. Redox Biology, 10, 90–99. https://doi.org/10.1016/j.redox.2016.09.013
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021). Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. The Korean Journal of Parasitology, 59(3), 189–225. https://doi.org/10.3347/kjp.2021.59.3.189
Ding, Y., Zhang, Z., Ding, C., Xu, S., & Xu, Z. (2023). The use of cyclodextrin inclusion complexes to increase the solubility and pharmacokinetic profile of albendazole. Molecules, 28(21), Article 7295. https://doi.org/10.3390/molecules28217295
Gallia, G. L., Holdhoff, M., Brem, H., Joshi, A. D., Hann, C. L., Bai, R.-Y., Staedtke, V., Blakeley, J. O., Sengupta, S., Jarrell, T. C., Wollett, J., Szajna, K., Helie, N., Mattox, A. K., Ye, X., Rudek, M. A., & Riggins, G. J. (2021). Mebendazole and re-irradiation, temozolomide, or levamisole/CCNU in patients with recurrent high-grade glioma: Phase 1 clinical trial results. Neuro-Oncology Advances, 3(1), Article vdaa154. https://doi.org/10.1093/noajnl/vdaa154
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023). The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. European Journal of Pharmacology, 949, Article 175586. https://doi.org/10.1016/j.ejphar.2023.175586
Golla, U., Patel, S., Shah, N., Talamo, S., Bhalodia, R., Claxton, D., Dovat, S., & Sharma, A. (2024). From deworming to cancer therapy: Benzimidazoles in hematological malignancies. Cancers, 16(20), Article 3454. https://doi.org/10.3390/cancers16203454
Han, Y., & Joo, H.-G. (2020). Involvement of reactive oxygen species in the anti-cancer activity of fenbendazole, a benzimidazole anthelmintic. Korean Journal of Veterinary Research, 60(2), 79–83. https://doi.org/10.14405/kjvr.2020.60.2.79
Huang, H., He, Q., Guo, B., Xu, X., Wu, Y., & Li, X. (2021). Progress in redirecting antiparasitic drugs for cancer treatment. Drug Design, Development and Therapy, 15, 2747–2767. https://doi.org/10.2147/DDDT.S309062
Kim, U., Shin, C., Kim, C.-Y., Ryu, B., Kim, J., Baek, J., & Park, J.-H. (2021). Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation. Oncology Letters, 21(5), Article 356. https://doi.org/10.3892/ol.2021.12656
LeapSpace. (2026). Albendazole and cancer literature compilation: Newest first [Working paper list].
Liaqat, I., Omer, M. O., Rasheed, M. A., & Raza, S. (2024). Preparation, characterization and in vitro anticancer evaluation of albendazole-loaded zinc oxide nanoparticles. Pakistan Veterinary Journal, 44(4), 1338–1344. https://doi.org/10.29261/pakvetj/2024.282
Mansoori, S., Fryknäs, M., Alvfors, C., Loskog, A., Larsson, R., & Nygren, P. (2021). A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports, 11, Article 8981. https://doi.org/10.1038/s41598-021-88433-y
Noorani, L., Pourgholami, M. H., Liang, M., Morris, D. L., & Stenzel, M. (2014). Albendazole loaded albumin nanoparticles for ovarian cancer therapy. European Journal of Nanomedicine, 6(4), 227–236. https://doi.org/10.1515/ejnm-2014-0026
Nuciforo, S., Blukacz, L., Heusler, M.-A., Booij, T. H., Kübler, L., Trulsson, F., Boldanova, T., Wang, X., Ketterer, S., Matter, M. S., Stirnimann, C. U., Wieland, S., & Heim, M. H. (2026). Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors. Cell Reports, 45(9), Article 117895. https://doi.org/10.1016/j.celrep.2026.117895
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancermedicalscience, 8, Article 443. https://doi.org/10.3332/ecancer.2014.443
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011). Albendazole sensitizes cancer cells to ionizing radiation. Radiation Oncology, 6, Article 160. https://doi.org/10.1186/1748-717X-6-160
Patil, V. M., Bhelekar, A., Menon, N., Bhattacharjee, A., Simha, V., Abhinav, R., Abhyankar, A., Sridhar, E., Mahajan, A., Puranik, A. D., Purandare, N., Janu, A., Ahuja, A., Krishnatry, R., Gupta, T., & Jalali, R. (2020). Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. Cancer Medicine, 9(13), 4676–4685. https://doi.org/10.1002/cam4.3094
Popović, D. J., Poša, M., Popović, K. J., Kolarović, J., Popović, J. K., & Banović, P. Z. (2017). Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology. Tropical Journal of Pharmaceutical Research, 16(10), 2555–2562. https://doi.org/10.4314/tjpr.v16i10.32
Pourgholami, M. H., Yan, C. M., & Morris, D. L. (2009). Albendazole impairs growth of paclitaxel-resistant ovarian cancer cells. Anticancer Research, 29(10), 3791–3796.
Pourgholami, M. H., Szwajcer, M., & Morris, D. L. (2010). Albendazole causes intracellular ATP depletion and induces apoptosis in human ovarian cancer cells. Anticancer Research, 30(2), 423–428.
Racoviceanu, R., Trandafirescu, C., Voicu, M., Ghiulai, R., Borcan, F., Dehelean, C., Watz, C., Aigner, Z., Ambrus, R., Coricovac, D. E., Cîrcioban, D., Mioc, A., Szuhanek, C. A., & Şoica, C. (2020). Solid polymeric nanoparticles of albendazole: Synthesis, physico-chemical characterization and biological activity. Molecules, 25(21), Article 5130. https://doi.org/10.3390/molecules25215130
Virlley, S., Arya, M., Singh, A., Havelikar, U., Raj, S., Meehnian, H., Dhamija, I., Singh, C., & Kumar, S. (2026). Drug delivery and repurposing approaches for albendazole formulations. BIO Integration, 7(1), Article bioi20250045. https://doi.org/10.15212/bioi20250045
Williamson, T., Bai, R.-Y., Staedtke, V., Huso, D., & Riggins, G. J. (2016). Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget, 7(42), 68571–68584. https://doi.org/10.18632/oncotarget.11851
Yang, M. H., Ha, I. J., Um, J.-Y., & Ahn, K. S. (2021). Albendazole exhibits anti-neoplastic actions against gastric cancer cells by affecting STAT3 and STAT5 activation by pleiotropic mechanism(s). Biomedicines, 9(4), Article 362. https://doi.org/10.3390/biomedicines9040362